Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial

• Published in: British journal of cancer 2020-11, Vol.123 (11), p.1616-1624
• Main Authors: Xie, Congying, Jing, Zhao, Luo, Honglei, Jiang, Wei, Ma, Li, Hu, Wei, Zheng, Anping, Li, Duojie, Ding, Lingyu, Zhang, Hongyan, Xie, Conghua, Lian, Xilong, Du, Dexi, Chen, Ming, Bian, Xiuhua, Tan, Bangxian, Xia, Bing, Xie, Ruifei, Liu, Qing, Wang, Lvhua, Wu, Shixiu
• Format: Article
• Language: English
• Subjects: 692/308/2779/777; 692/4028/67/1504/1477; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Biomedical and Life Sciences; Biomedicine; Cancer Research; Chemoradiotherapy; Chemoradiotherapy - methods; Chemotherapy; Cisplatin; Cisplatin - administration & dosage; Drug Resistance; Epidemiology; Epidermal growth factor; Epidermal growth factor receptors; Erlotinib Hydrochloride - administration & dosage; Esophageal cancer; Esophageal Neoplasms - therapy; Esophageal Squamous Cell Carcinoma - therapy; Esophagus; Female; Humans; Inhibitor drugs; Lymph Nodes - radiation effects; Male; Middle Aged; Molecular Medicine; Oncology; Paclitaxel; Paclitaxel - administration & dosage; Patients; Radiation therapy; Squamous cell carcinoma; Targeted cancer therapy
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/s41416-020-01054-6

Background To report the long-term outcomes of a phase III trial designed to test two hypotheses: (1) elective nodal irradiation (ENI) is superior to conventional field irradiation (CFI), and (2) chemoradiotherapy plus erlotinib is superior to chemoradiotherapy in locally advanced oesophageal squamous cell cancer (ESCC). Methods Patients with locally advanced ESCC were randomly assigned (1:1:1:1 ratio) to one of the four groups: A: radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib; B: radiotherapy adoption of ENI with two cycles of concurrent TP; C: radiotherapy adoption of CFI with two cycles of concurrent TP plus erlotinib and D: radiotherapy adoption of CFI with two cycles of concurrent TP. A total of 60 Gy of radiation doses was delivered over 30 fractions. We explored the impact of epidermal growth factor receptor (EGFR) expression on the efficacy of erlotinib plus chemoradiotherapy. Results A total of 352 patients (88 assigned to each treatment group) were enrolled. The 5-year survival rates were 44.9%, 34.8%, 33.8% and 19.6% in groups A, B, C and D, respectively ( P  = 0.013). ENI significantly improved OS compared with standard CFI (median, 38.5 vs 22.6 months; HR, 0.74; P  = 0.018). The addition of erlotinib significantly improved OS (median, 39.4 vs 27.4 months; HR, 0.75; P  = 0.025). Patients with overexpressing EGFR treated with erlotinib had a better OS and PFS than those without erlotinib. Conclusions Concurrent chemoradiotherapy with ENI and/or erlotinib improved long-term survival in locally advanced ESCC. Clinical trial registration Trial registration: NCT00686114.